EN DE
Watch Panacea Biotec Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Panacea Biotec Limited (PANACEABIO) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Panacea Biotec Limited stock ₹303, price ₹361, that is 16.0% below the price, quality 48 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE922B01023

PB Panacea Biotec Limited logo Thin data Nov 10, 2026

Panacea Biotec Limited

PANACEABIO · NSE
Expensive, weak quality

Our calculation puts a fair price 16% below what the stock costs today.

Low debt
Ranks above peers (8/10)
Revenue last quarter +20% vs. a year ago.
Quality 48/100
Fair value ₹302.83 · Overvalued
Weak Growth (revenue 5y +0.7 %/yr in INR)
Loss-making · -1.1% net margin (TTM)
Negative free cash flow
Narrow moat 18/100 · thin data
Thin data
Estimate
Watch Panacea Biotec Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹607.75 ₹107.55 Fair Value ₹302.83 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range ₹107.55 – ₹607.75 · fair‑value band ₹227.12 – ₹378.54 · the ₹360.65 price screens above the ₹302.83 fair value. As of Nov 10, 2026.

Follow Panacea Biotec in your weekly email

Every Wednesday you see whether Panacea Biotec is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally.

Show moreShow less

It operates through Vaccines and Pharmaceutical formulations & Nutrition segments.

The company's product portfolio includes prescription products in various therapeutic areas, such as oncology, diabetes, gastro-intestinal care, nephrology, orthopedics, pain management, and fever; cold and cough; and betacoronavirus, SARS-CoV-2, typhoid conjugate, pneumococcal conjugate, tetravalent dengue, Mpox, and hepatitis A vaccines, etc.

It also offers health supplement products; and paediatric nutrition products under the ChilRunFull, ChilRun 7+, and ChillRun No Sucrose brands. In addition, the company engages in the real estate business. It exports its products to approximately 50 countries.

The company has collaboration agreements with the Russian Direct Investment Fund for producing Covid-19 vaccine, and Sputnik-V; and the Indian Council of Medical Research for clinical trials of DengiAll vaccine. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.

Stock analysis

Panacea Biotec Limited (PANACEABIO) currently trades at ₹360.65, while our estimate is ₹302.83, 16% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: ₹227.12 (bear) to ₹378.54 (bull), the price of ₹360.65 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Panacea Biotec Limited reported revenue of ₹6.4B in FY2026 versus ₹6.6B in FY2022, a compound −0.7%/yr. Reported net income was −₹53.7M in FY2026.

Key figures

Market cap ₹22.0B (≈ $234M) Micro · P/S ratio 2.96 · EPS (TTM) ₹−1.16 · Net margin −1.1% · Return on equity −0.9% · Return on assets (EBIT) −4.0% (5-year average) · Operating margin −1.1% · Revenue (TTM) ₹6.7B.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (low confidence).

What moves the price

The share trades about 41% below its 52-week high and 22% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −16%, PANACEABIO screens richer than that median.

Fair Value

Bear ₹227.12 Fair Value ₹302.83 Bull ₹378.54
Price ₹360.65 · Downside -16.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 48/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 18
How much profit the company makes from its sales and capital
Quality Growth 41
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 79
Debt, balance sheet and risk of trouble
Investment 88
Does it invest with discipline instead of growing at any price?
Low Volatility 56
How calm the share price moves, does not count
Price momentum 27
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 22
Distance to the 52-week high, does not count
New shares 83
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 12/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+14.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.7%
Start year 2021 (pandemic). Over 10 years: −0.2% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
5.3% (2021) → −5.9% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

PANACEABIO screens overvalued: fair value 16% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Panacea Biotec Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 7/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 48 · Above median
Fair Value upside −16.0% · Above median
Profitability
Return on assets −0.4% · Top 25%
Net margin (12 months) −1.1% · Above median
Operating margin (12 months) −1.1% · Below median
Growth and dividend
Revenue growth (quarter YoY) 19.7% · Above median
Balance sheet
Debt / equity 0.03× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.64× · Pricier than median
P/S (12 months) 3.27× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)12 · sector 0
FUTURE (revenue growth)99 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)99 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs PANACEABIO
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs PANACEABIO
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs PANACEABIO
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs PANACEABIO
argenx SE ARGX $971.55 $908.40 −7% vs PANACEABIO
CSL Limited CSL A$201.68 A$181.40 −10% vs PANACEABIO
Moderna, Inc MRNA $250.83 $158.70 −37% vs PANACEABIO
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs PANACEABIO
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs PANACEABIO
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs PANACEABIO

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Panacea Biotec Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Panacea Biotec Limited Fair Value". https://www.fairvalue-calculator.com/stock/PANACEABIO

Frequently asked questions

Is Panacea Biotec Limited (PANACEABIO) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is ₹302.83 versus a price of ₹360.65, about 16% lower (overvalued).
What is the fair value of PANACEABIO?
Our estimate for Panacea Biotec Limited is ₹302.83 (as of Nov 10, 2026), built from audited fundamentals. The current price: ₹360.65.
What is the quality score of PANACEABIO?
Panacea Biotec Limited has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Panacea Biotec Limited (PANACEABIO)?
Our calculated price target is the estimate of ₹302.83 (as of Nov 10, 2026). Cautious scenario ₹227.12, optimistic scenario ₹378.54. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Panacea Biotec Limited stock forecast for 2026?
Our estimate puts fair value at ₹302.83, about 16% lower versus a price of ₹360.65 (overvalued). Cautious scenario ₹227.12, optimistic scenario ₹378.54. The calculation is refreshed regularly with new filings.
What is the revenue of Panacea Biotec Limited (PANACEABIO)?
Panacea Biotec Limited reported trailing-twelve-month revenue of about ₹6.7B (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Panacea Biotec Limited (PANACEABIO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Panacea Biotec Limited it is ₹302.83 per share (as of Nov 10, 2026), against a price of ₹360.65.
Is Panacea Biotec Limited stock overvalued or undervalued in 2026?
As of Nov 10, 2026, PANACEABIO trades above its calculated fair value: price ₹360.65, fair value ₹302.83, a gap of about −16% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PANACEABIO?
No. The price is what the market pays today (₹360.65); the fair value is what the company's own numbers justify (₹302.83). For Panacea Biotec Limited the two are ₹57.82 per share apart. That gap is exactly why we show both numbers side by side.
How much is Panacea Biotec Limited worth?
The market values Panacea Biotec Limited at about ₹22.0B (market capitalisation, as of Nov 10, 2026). Per share that is ₹360.65; our models calculate a fair value of ₹302.83 per share.
What do the bullish and bearish scenarios say about PANACEABIO?
Our models span a range for Panacea Biotec Limited: cautious scenario ₹227.12, base ₹302.83, optimistic ₹378.54 per share (as of Nov 10, 2026, price ₹360.65). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Panacea Biotec Limited (PANACEABIO)?
Balance-sheet figures for Panacea Biotec Limited (as of Nov 10, 2026): return on equity −0.9%, debt of 0.03 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is PANACEABIO from its 52-week high?
Panacea Biotec Limited trades at ₹360.65, about 41% below its 52-week high of ₹607.75 and 22% above the low of ₹296.05 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of ₹302.83 is for.
Which stocks are comparable to Panacea Biotec Limited?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Panacea Biotec Limited stock attractive at the current price?
The data as of Nov 10, 2026: price ₹360.65, calculated fair value ₹302.83 (−16%), Quality Score 48/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Panacea Biotec Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Panacea Biotec Limited (PANACEABIO)?
The closing price on Nov 9, 2026 was ₹360.65. Our estimate is ₹302.83, about 16% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Panacea Biotec Limited right now?
Weak quality (48/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Panacea Biotec Limited

How large is the market capitalisation of Panacea Biotec Limited (PANACEABIO)?
The market capitalisation of Panacea Biotec Limited is ₹22.0B (≈ $234M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Panacea Biotec Limited (PANACEABIO)?
The price-to-sales ratio of Panacea Biotec Limited is 2.96 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Panacea Biotec Limited (PANACEABIO)?
Earnings per share at Panacea Biotec Limited are ₹−1.16. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Panacea Biotec Limited (PANACEABIO)?
The net margin of Panacea Biotec Limited is −1.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Panacea Biotec Limited (PANACEABIO)?
The return on equity (ROE) of Panacea Biotec Limited is −0.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Panacea Biotec Limited (PANACEABIO)?
On an EBIT basis the return on assets of Panacea Biotec Limited is −4.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Panacea Biotec Limited (PANACEABIO)?
The operating margin of Panacea Biotec Limited is −1.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Panacea Biotec Limited (PANACEABIO)?
Revenue at Panacea Biotec Limited is growing +19.7% versus a year earlier (3y avg +11.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Panacea Biotec Limited (PANACEABIO)?
Earnings per share at Panacea Biotec Limited are growing −42.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Panacea Biotec Limited (PANACEABIO) generate?
The free cash flow of Panacea Biotec Limited is −₹368M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Panacea Biotec Limited (PANACEABIO) hold?
Panacea Biotec Limited holds more cash than debt, ₹407M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Panacea Biotec Limited in the live analysis

One click puts Panacea Biotec Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.